ArticleHaematologica2012
Lack and/or aberrant localization of major histocompatibility class II (MHCII) protein in plasmablastic lymphoma.
Article in Haematologica, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520.Leukemia & lymphoma · 2016Trial
- Testicular aggressive B-cell lymphoma with plasmablastic morphology harboring concurrent IGH::MYC and IGH::BCL2 rearrangements.Journal of hematopathology · 2026Article
- KSHV infection of B cells primes protective T cell responses in humanized mice.Nature communications · 2024Article
- Plasmablastic Lymphoma. A State-of-the-Art Review: Part 1-Epidemiology, Pathogenesis, Clinicopathologic Characteristics, Differential Diagnosis, Prognostic Factors, and Special Populations.Mediterranean journal of hematology and infectious diseases · 2024Review
- Biological and clinical significance of epigenetic alterations in B-cell lymphomas.International journal of hematology · 2022Review
- Plasmablastic lymphoma: An update.International journal of laboratory hematology · 2022Review
- Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma.Haematologica · 2021Article
- Aberrant cytoplasmic expression of MHCII confers worse progression free survival in diffuse large B-cell lymphoma.Virchows Archiv : an international journal of pathology · 2017Article
- Manifestations of gastrointestinal plasmablastic lymphoma: a case series with literature review.World journal of gastroenterology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.